IDEAYA Biosciences Inc
NASDAQ:IDYA

Watchlist Manager
IDEAYA Biosciences Inc Logo
IDEAYA Biosciences Inc
NASDAQ:IDYA
Watchlist
Price: 26.995 USD 1.48% Market Closed
Market Cap: 2.3B USD
Have any thoughts about
IDEAYA Biosciences Inc?
Write Note

Relative Value

The Relative Value of one IDYA stock under the Base Case scenario is 11.022 USD. Compared to the current market price of 26.995 USD, IDEAYA Biosciences Inc is Overvalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IDYA Relative Value
Base Case
11.022 USD
Overvaluation 59%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
0
vs Industry
10
Median 3Y
27.7
Median 5Y
23.1
Industry
7.7
Forward
322.4
vs History
vs Industry
Median 3Y
-16.2
Median 5Y
-14.9
Industry
22.7
Forward
-10.9
vs History
vs Industry
6
Median 3Y
-13.8
Median 5Y
-8.9
Industry
21.6
vs History
vs Industry
5
Median 3Y
-13.6
Median 5Y
-8.5
Industry
25.2
vs History
53
vs Industry
25
Median 3Y
2.6
Median 5Y
2.4
Industry
2.5
vs History
0
vs Industry
10
Median 3Y
17.6
Median 5Y
12.6
Industry
7.7
Forward
195.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-8.3
Industry
4.2
Forward
-5.9
vs History
vs Industry
Median 3Y
-9.4
Median 5Y
-8
Industry
4.1
Forward
-5.7
vs History
vs Industry
7
Median 3Y
-9.2
Median 5Y
-4.5
Industry
5.7
vs History
vs Industry
7
Median 3Y
-9
Median 5Y
-4.3
Industry
3.6
vs History
60
vs Industry
21
Median 3Y
9.7
Median 5Y
9.3
Industry
4.6

Multiples Across Competitors

IDYA Competitors Multiples
IDEAYA Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
2.3B USD 594.4 -13.1 -6.3 -6.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.7B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
157B USD 4.8 37.1 17.4 32.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD 4 890.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 6 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
P/E Multiple
Earnings Growth
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
Average P/E: 208
Negative Multiple: -13.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.1
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
890.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
EV/EBITDA Multiple
EBITDA Growth
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
Average EV/EBITDA: 17.2
Negative Multiple: -6.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.4
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
EV/EBIT Multiple
EBIT Growth
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
Average EV/EBIT: 22.5
Negative Multiple: -6.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
32.9
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A

See Also

Discover More
Back to Top